Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin in Subjects With Genotype 1 Chronic Hepatitis C Infection

NCT01011166 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT01011166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01011166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin in Subjects With Genotype 1 Chronic Hepatitis C Infection
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
July 31, 2010
Enrollment
81 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c infection